Gilder Gagnon Howe & Co’s Blueprint Medicines BPMC Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-4	Closed	–	–	283
2019 Q4	$0	Hold	4	–	–	﹤0.01%	290
2019 Q3	$0	Buy	+4	New	+$346	﹤0.01%	286
2015 Q3	–	Sell	-4,710	Closed	-$125K	–	262
2015 Q2	$125K	Buy	+4,710	New	+$135K	﹤0.01%	253

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Gilder Gagnon Howe & Co's BPMC Position: Q1 2020 in Review

Gilder Gagnon Howe & Co sold out of Blueprint Medicines (BPMC) in Q1 2020, closing a stake of 4 shares.

Gilder Gagnon Howe & Co first reported a position in BPMC in Q2 2015 and held it in 3 quarters. The position peaked at $125K in Q2 2015. 213 funds tracked by Wall St. Rank hold BPMC as of Q1 2020.

Gilder Gagnon Howe & Co reported no remaining Blueprint Medicines position as of Q1 2020 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 4 Blueprint Medicines shares in Q1 2020.
Gilder Gagnon Howe & Co first reported a position in Blueprint Medicines in Q2 2015 and held it in 3 quarters.
Gilder Gagnon Howe & Co's Blueprint Medicines position peaked at $125K in Q2 2015.
213 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2020.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2020, filed 15 May 2020.